Vanguard Group Inc. Has $100.26 Million Stock Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Vanguard Group Inc. lessened its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 2.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,424,734 shares of the company's stock after selling 71,378 shares during the quarter. Vanguard Group Inc. owned about 5.05% of Mirum Pharmaceuticals worth $100,263,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in MIRM. Lord Abbett & CO. LLC acquired a new position in shares of Mirum Pharmaceuticals in the 3rd quarter valued at $28,913,000. State Street Corp increased its holdings in shares of Mirum Pharmaceuticals by 19.9% in the third quarter. State Street Corp now owns 1,793,728 shares of the company's stock worth $69,955,000 after acquiring an additional 297,511 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Mirum Pharmaceuticals during the fourth quarter worth about $10,611,000. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Mirum Pharmaceuticals by 162.6% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 176,960 shares of the company's stock valued at $7,317,000 after purchasing an additional 109,585 shares in the last quarter. Finally, Wellington Management Group LLP grew its position in shares of Mirum Pharmaceuticals by 62.2% in the 3rd quarter. Wellington Management Group LLP now owns 122,334 shares of the company's stock valued at $4,771,000 after purchasing an additional 46,918 shares during the period.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Robert W. Baird upped their price target on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an "outperform" rating in a report on Thursday, February 27th. HC Wainwright increased their target price on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Buy" and an average target price of $58.20.

Insider Buying and Selling at Mirum Pharmaceuticals

In other news, insider Joanne Quan sold 6,969 shares of the company's stock in a transaction that occurred on Friday, January 17th. The stock was sold at an average price of $45.86, for a total value of $319,598.34. Following the transaction, the insider now owns 5,649 shares of the company's stock, valued at approximately $259,063.14. This represents a 55.23 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Jolanda Howe sold 57,606 shares of the business's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $44.35, for a total value of $2,554,826.10. Following the completion of the sale, the senior vice president now owns 4,841 shares of the company's stock, valued at $214,698.35. This trade represents a 92.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 123,442 shares of company stock worth $5,568,733 over the last 90 days. Company insiders own 22.87% of the company's stock.

Mirum Pharmaceuticals Stock Down 1.4 %

Shares of Mirum Pharmaceuticals stock traded down $0.54 on Tuesday, reaching $39.05. 63,692 shares of the company were exchanged, compared to its average volume of 520,611. Mirum Pharmaceuticals, Inc. has a one year low of $23.14 and a one year high of $54.23. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. The company has a 50-day moving average of $46.17 and a 200 day moving average of $44.04. The company has a market capitalization of $1.91 billion, a price-to-earnings ratio of -19.33 and a beta of 1.00.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.22). The firm had revenue of $99.41 million during the quarter, compared to the consensus estimate of $96.64 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. On average, equities research analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.